Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity
Diabetes Care · 01.11.2024 · 47 (11) · 1873-1888
DOI: 10.2337/dci24-0003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes Care, online erschienen am 06.06.2024. Verfasst von Daniel J Drucker. Beteiligte Einrichtung: Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Obesity, Glucagon-Like Peptide 1, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 394-mal zitiert (Crossref) und nennt 167 Literaturangaben. Gefördert von: Canadian Institutes for Health Research.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2 diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA in select patient populations. In ongoing trials investigators are interrogating the efficacy of these agents for new indications, including metabolic liver disease, peripheral artery disease, Parkinson disease, and Alzheimer disease. The success of GLP-1–based medicines has spurred the development of new molecular entities and combinations with unique pharmacokinetic and pharmacodynamic profiles, exemplified by tirzepatide, a GIP-GLP-1 receptor coagonist. Simultaneously, investigational molecules such as maritide block the GIP and activate the GLP-1 receptor, whereas retatrutide and survodutide enable simultaneous activation of the glucagon and GLP-1 receptors. Here I highlight evidence establishing the efficacy of GLP-1–based medicines, while discussing data that inform safety, focusing on muscle strength, bone density and fractures, exercise capacity, gastrointestinal motility, retained gastric contents and anesthesia, pancreatic and biliary tract disorders, and the risk of cancer. Rapid progress in development of highly efficacious GLP-1 medicines, and anticipated differentiation of newer agents in subsets of metabolic disorders, will provide greater opportunities for use of personalized medicine approaches to improve the health of people living with cardiometabolic disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Canada.
ORCID-Profile: Daniel J Drucker
Förderung
- Canadian Institutes for Health Research
Zitieren
APA
Drucker, D. J. (2024). Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care, 47(11), 1873-1888. https://doi.org/10.2337/dci24-0003
Vancouver
Drucker DJ. Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care. 2024;47(11):1873-1888. doi:10.2337/dci24-0003
BibTeX
@article{Drucker2024,
author = {Drucker, Daniel J},
title = {Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity},
journal = {Diabetes Care},
year = {2024},
volume = {47},
number = {11},
pages = {1873--1888},
doi = {10.2337/dci24-0003}
}
EUVIMED